Antimicrobials
Remdesivir

Remdesivir

N/A
N/A
Currently N/A

Spectrum of Activity

General Information

As guided by Ontario COVID-19 Science Advisory Table (OSAT):

  • Remdesivir is recommended for moderately ill patients (patients newly requiring low-flow supplemental oxygen) with COVID-19 presenting within 10 days of symptom onset
  • Remdesivir may be considered for critically ill COVID-19 patients requiring high-flow oxygen or noninvasive ventilation who present within 10 days of symptom onset
    • Remdesivir is NOT recommended for critically ill patients with COVID-19 receiving mechanical ventilation

As guided by OSAT and Ontario Health recommendations:

  • Remdesivir is a recommended treatment option for mildly ill COVID-19 patients (who do not require new or additional supplemental oxygen from their baseline status) IF they present within 7 days of symptom onset AND they meet higher risk criteria as per Ontario Health recommendations:
    • 60 years or older
    • 18-59 years old who are immunocompromised
    • 18-59 years old who are at higher risk of severe COVID-19

Renal and hepatic function should be monitored at baseline and ongoing while on remdesivir.

  • Hypersensitivity Including Infusion-Related and Anaphylactic Reactions
    • Slower infusion rates can be considered
  • Rash
  • GI intolerance
  • Headache
  • Hyperglycemia
  • Increased hepatic enzymes
  • Increased creatinine
  • Bradycardia

Chloroquine or Hydroxychloroquine - risk of reduced antiviral activity (avoid coadministration).

Antimicrobial class: Adenosine nucleotide prodrug antiviral

Average serum half life: ~1 hour (metabolite ~25 hours)

Lung penetration: Therapeutic (widely distributed)